March 19, 2020 / 8:43 PM / 11 days ago

BRIEF-Curis Reports Fourth Quarter And Year-End 2019 Financial Results And Provides Business Update

March 19 (Reuters) - Curis Inc:

* CURIS REPORTS FOURTH QUARTER AND YEAR-END 2019 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

* Q4 LOSS PER SHARE $0.26

* DISCONTINUING FIMEPINOSTAT-VENETOCLAX COMBINATION STUDY

* PRIORITIZING RESOURCES FOR CA-4948 AND CI-8993 CLINICAL DEVELOPMENT PROGRAMS

* ENTERED INTO A COMMON STOCK PURCHASE AGREEMENT WITH ASPIRE CAPITAL

* QTRLY TOTAL REVENUES, NET $3.3 MILLION VERSUS $2.8 MILLION

* QTRLY NET LOSS PER COMMON SHARE $0.26

* EXPECTS EXISTING CASH, CASH EQUIVALENTS & INVESTMENTS SHOULD ENABLE CO TO MAINTAIN PLANNED OPERATIONS INTO H2 2020 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below